About Us Strategy & Mission Our Values Our People Our Board Our Collaborations Contact Our Programmes Overview Pipeline C. difficile Infection Gonorrhoea Enterobacteriaceae ESKAPE Programme Clinical Trials Stewardship Compassionate Use Our Science Discuva Platform Publications Investors Investor Centre Press Releases Financial Reports & Filings Email Alerts Events & Presentations Share Price Data Shareholder Information Analyst Coverage Corporate Governance Company Information Advisers Shareholder Meetings Careers
Press Releases Our latest press releases are available to read in this section Press Releases Date Range Explore Search Press Releases / 03 Oct 2019 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care Press Releases / 25 Sep 2019 Summit to Host R&D Day 7 October 2019 Press Releases / 24 Sep 2019 Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Press Releases / 18 Sep 2019 Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes Press Releases / 05 Sep 2019 Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference Press Releases / 01 Aug 2019 Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Press Releases / 17 Jul 2019 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Press Releases / 09 Jul 2019 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia Press Releases / 20 Jun 2019 Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Press Releases / 18 Jun 2019 Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option Press Releases / 12 Jun 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Press Releases / 14 Apr 2019 Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019 << 1 2 3 … 26 27 >>
Press Releases / 03 Oct 2019 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care Press Releases / 25 Sep 2019 Summit to Host R&D Day 7 October 2019 Press Releases / 24 Sep 2019 Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019 Press Releases / 18 Sep 2019 Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes Press Releases / 05 Sep 2019 Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference Press Releases / 01 Aug 2019 Summit Therapeutics to Present at the Canaccord Genuity Growth Conference Press Releases / 17 Jul 2019 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Press Releases / 09 Jul 2019 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia Press Releases / 20 Jun 2019 Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Press Releases / 18 Jun 2019 Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option Press Releases / 12 Jun 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Press Releases / 14 Apr 2019 Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
Press Releases / 03 Oct 2019 Summit Therapeutics Reports Ridinilazole Significantly Improved Short and Longer-Term Quality of Life Measures in Patients with C. difficile Infection Compared to Standard of Care
Press Releases / 24 Sep 2019 Summit Therapeutics to Present Data from Phase 2 Clinical Trial of Ridinilazole at ID Week 2019
Press Releases / 18 Sep 2019 Summit Announces Publication of Editorial in Future Microbiology Advocating for Innovation in Antibiotic Development to Drive Stewardship Focus on Improving Patient Outcomes
Press Releases / 05 Sep 2019 Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference
Press Releases / 01 Aug 2019 Summit Therapeutics to Present at the Canaccord Genuity Growth Conference
Press Releases / 17 Jul 2019 Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
Press Releases / 09 Jul 2019 Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
Press Releases / 20 Jun 2019 Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
Press Releases / 18 Jun 2019 Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option
Press Releases / 12 Jun 2019 Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
Press Releases / 14 Apr 2019 Summit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
